Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today ...
For most companies, the honest answer is: nobody knows.
DRILLAPP JavaScript backdoor targets Ukraine in Feb 2026, abusing Edge debugging features to spy via camera, microphone, and ...
LGBTQ Nation on MSN
RFK tried to ban trans care for minors. A federal judge just stopped him.
The judge said he didn't follow the correct procedure for what is effectively a move to deny patients care.
The campaign, observed in February 2026, has been assessed to share overlaps with a prior campaign mounted by Laundry Bear, a ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the 11 most popular AI penny stocks to buy now. On February 25, Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) reported Q4 revenue of $35.5 million ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
On February 25, Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) reported Q4 revenue of $35.5 million compared to the consensus estimates of $24.6 million. The company’s cash, cash equivalents, and ...
Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.44, moving -1.99% from the previous trading session. This change lagged the S&P 500's 0.21% loss on the day. Meanwhile, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results